Tag Archive for: PSMA

UPDATE: Phase 1 GenSci143 Trial Set To Start By The End of December

We have already talked about it here, GenSci143, is a novel bispecific antibody-drug conjugate targeting B7-H3 and PSMA, and a phase 1 trial is set to begin first-in-human clinical trials soon (est. date December 20) in participants with advanced solid tumors, including metastatic castration-resistant prostate cancer. Recent regulatory approvals were granted by the U.S. FDA […]

APVO442: A Promising Preclinical Candidate in the Fight Against Prostate Cancer

A Seattle-based biotech, is stepping up with APVO442, a promising preclinical bispecific antibody aimed at transforming prostate cancer treatment by unleashing the body’s immune system against tumors with greater precision and fewer side effects. Built on proprietary ADAPTIR-FLEX platform, APVO442 is designed to target prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer […]

Phase 1 Recruiting: ABBV-969, A Novel Bispecific Antibody Drug Conjugate for Advanced Prostate Cancer

CTT2274: A Potential Game-Changer for Metastatic Prostate Cancer Treatment…start hating the word “potential”

ARX517 Achieves Key Safety and Efficacy Milestones in Phase 1/2 Trials for Metastatic Castration-Resistant Prostate Cancer